**National Institute for Health and Care Excellence**

### Surveillance Review of CG134 Anaphylaxis: assessment and referral after emergency treatment

### Stakeholder Comments Form

|  |  |
| --- | --- |
| **Please enter the name of your registered stakeholder organisation below.**  **NICE is unable to accept comments from non-registered organisations. If you wish your comments to be considered please register via the** [**NICE website**](http://www.nice.org.uk/get-involved/stakeholder-registration) **or contact the** [**registered stakeholder organisation**](https://www.nice.org.uk/guidance/CG134/documents/stakeholder-list) **that most closely represents your interests and pass your comments to them.** | |
| Stakeholder Organisation: |  |
| Name of commentator: |  |

***Please note an overview of the process for reviewing NICE published clinical guidelines can be found*** [**here**](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/developing-NICE-guidelines-the-manual.pdf)

**Contents:**

* Comments on proposal not to update the guideline – page 2
* Comments on the proposal to put the guideline on the static list – page 2
* Comments on the proposal to remove research recommendations from the NICE version of the guideline and the NICE research recommendations database – page 3
* Comments on equality issues or areas excluded from the guideline scope – page 3

**Proposal not to update the guideline**

In order to guide your comments, please refer to the following questions:

1. Do you agree that the guidance should not be updated?
2. Do you agree with our proposal to put the guideline on the static list?
3. Do you agree with our proposal to remove the listed research recommendations from the NICE version of the guideline and the NICE research recommendation database?

If a stakeholder wishes to draw our attention to published literature, please supply the full reference. Please add extra rows as needed

| **1. Do you agree the guideline should not be updated?** | **Comments**  **If you disagree, please explain why** |
| --- | --- |
| Agree / Disagree (please delete as appropriate) | Comments on proposal not to update the guideline |

| **2. Do you agree with the proposal to put the guideline on the static list?** | **Comments**  **If you disagree, please explain why** |
| --- | --- |
| Agree / Disagree (please delete as appropriate) | Comments on proposal to put the guideline on the static list |

| **2. Do you agree with the proposal to remove these research recommendations from the NICE version and research database?** | | **Comments**    **If you disagree, please explain why** |
| --- | --- | --- |
| Aside from mast cell tryptase, which other chemical inflammatory mediators offer potential as indicators of anaphylaxis? | | |
| Agree / Disagree (please delete as appropriate) | Comments on proposal to remove these research recommendations from the NICE version and research database | |
| For how long should a person who has received emergency treatment for anaphylaxis be observed? | | |
| Agree / Disagree (please delete as appropriate) | Comments on proposal to remove these research recommendations from the NICE version and research database | |

# Do you have any comments on equality issues or areas excluded from the original scope?

|  |
| --- |
|  |

**Please email this form to:** [**surveillance@nice.org.uk**](mailto:surveillance@nice.org.uk)

**Closing date: 5pm Friday 9 September 2016**

**PLEASE NOTE:** The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion or the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.